In the same year, the Phase II RENOBATE trial (42 HCC patients received nivolumab combined with regorafenib) observed an increase in the proportion of Ki-67+ cells and GZMB+ perforin+ cells in CD8+ T cells and PD-1+CD8+ T cells only in patients with CR/PR > 10 months after treatment [100]. This evidence concerns the gene MKI67 and hepatocellular carcinoma.